Prostate Cell News Volume 10.31 | Aug 23 2019

TOP STORY

The Δ133p53β Isoform Promotes an Immunosuppressive Environment Leading to Aggressive Prostate Cancer

RNA-seq of tumors showed enrichment for pathways associated with immune signaling and cell migration. Sceintists showed a role for hypoxia and wild-type p53 in upregulating Δ133TP53 levels. [Cell Death Dis] Full Article

(Ranked by impact factor of the journal)

Caffeic Acid Phenethyl Ester Suppresses Androgen Receptor Signaling and Stability via Inhibition of Phosphorylation on Ser81 and Ser213

Fluorescence microscopy demonstrated that androgen promoted the nucleus translocation of androgen receptor (AR) in prostate cancer cells, while treatment with caffeic acid phenethyl ester reduced protein level of AR in both the nucleus and cytoplasm. [Cell Commun Signal] Full Article | Graphical Abstract

Differential Actions of Estrogen Receptor α and β via Non-Genomic Signaling in Human Prostate Stem and Progenitor Cells

Membrane-initiated estrogen signaling was interrogated in human prostate stem-progenitor cells enriched from primary epithelial cultures and stem-like cell lines from benign and cancerous prostates. [Endocrinology] Abstract

The Role of WNT10B in Normal Prostate Gland Development and Prostate Cancer

WNT10B mRNA levels were increased in the metastatic cell lines PC3, PC3M, as well as in HuSLC, a prostate cancer stem‐like cell line, as compared with disease‐free primary prostate epithelial cells. [Prostate] Abstract

Ouabain Induces Apoptotic Cell Death in Human Prostate DU 145 Cancer Cells through DNA Damage and TRAIL Pathways

Scientists indicated that ouabain induced cell morphological changes, decreased total cell viability, induced G0/G1 phase arrest, DNA damage, and cell apoptosis, increased ROS and Ca²⁺ production, but decreased the levels of ΔΨ_m in DU 145 cells. [Environ Toxicol] Abstract

A Molecule Inducing Androgen Receptor Degradation and Selectively Targeting Prostate Cancer Cells

Ex vivo, IRC117539-mediated androgen receptor (AR) degradation induced prostate cancer cell viability loss by inhibiting AR signaling, even in androgen-insensitive cells. [Life Sci Alliance] Full Article

Apoptotic Activity of Xanthoquinodin JBIR-99, from Parengyodontium album MEXU 30054, in PC-3 Human Prostate Cancer Cells

Cytotoxicity of xanthoquinodin was evaluated in a panel of human cancer cells lines and CCD-112-CoN normal colon cells, using the sulforhodamine B assay. PC-3 prostate cancer cells were used in biochemical assays including cell cycle, mitochondrial transmembrane potential, reactive oxygen species and caspase activity. [Chem Biol Interact] Abstract | Graphical Abstract

JAB1/COPS5 Is a Putative Oncogene that Controls Critical Oncoproteins Deregulated in Prostate Cancer

To test the function of c-Jun activation domain-binding protein 1 (JAB1) in prostate cancer (PCa), the authors efficiently silenced JAB1 expression using four unique shRNAs in three PCa cell lines and an immortalized prostate epithelial cell line, RWPE-1. [Biochem Biophys Res Commun] Abstract

Effects of Black Raspberries and Their Constituents on Rat Prostate Carcinogenesis and Human Prostate Cancer Cell Growth In Vitro

Black raspberry extract, the anthocyanin cyanidin-3-rutinoside and protocatechuic acid did not inhibit prostate cancer cell growth in vitro, but ellagic acid and its urolithin A metabolite did at high concentrations. [Nutr Cancer] Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer

Various immune cells including tumor-associated neutrophils, tumor-infiltrating macrophages, myeloid-derived suppressor cells, and mast cells promote prostate cancer via various intercellular signaling. Further basic studies examining the relationship between the inflammatory process and prostate cancer progression are warranted. [Cancers] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

US FDA Grants XTANDI^® (Enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer

Astellas Pharma Inc. and Pfizer Inc. announced that the FDA has accepted for review the filing of a supplemental New Drug Application for XTANDI^® to add an indication for the treatment of men with metastatic hormone-sensitive prostate cancer. [Astellas Pharma Inc.] Press Release

FDA Accepts IND Application for Novel Immunotherapeutic for Prostate Cancer in Development by Calibr at Scripps Research

Calibr announced that the FDA has cleared its investigational new drug application (IND) for CCW702, a novel immunotherapeutic for the treatment of patients with metastatic castration-resistant prostate cancer. [Scripps Research] Press Release

More Than 700 German Research Institutions Strike Open-Access Deal with Springer Nature

A consortium of more than 700 German research institutions and libraries announced an agreement with publisher Springer Nature to make it simpler for authors to publish their papers open access. The agreement is the largest national open-access deal to date, but it doesn’t allow authors to publish open access in Nature or its sister journals. [ScienceInsider] Editorial

As Brexit Nears, Britain’s Drugs, Devices and Pricing Regulators Seek the Exit

Firm details on exactly how the UK will regulate new medicines is still to be decided after it leaves the EU later this year, but we now know that the regulator won’t be run by Dr. Ian Hudson, who is stepping down after six years in charge. [FierceBiotech] Editorial

NEW Cancer Epigenetics: New Mechanisms and Therapeutic Opportunities
January 26-30, 2020
Keystone, Colorado, United States

Visit our events page to see a complete list of events in the community.

NEW Computational Postdoctoral Fellow – Single-Cell Epigenomics and 3D Genomes in Cancer (Princess Margaret Cancer Centre)

Scientific Communications Coordinator (STEMCELL Technologies Inc.)

Senior Research Assistant – Genitourinary Oncology (MD Anderson Cancer Center)

Professor/Associate Professor – Prostate Cancer (Uniformed Services University of the Health Sciences)

Postdoctoral Position – Prostate Cancer (Roswell Park Comprehensive Cancer Center)

Postdoctoral Scientist – Prostate Oncobiology (Cancer Research UK)

Research Officer – Tumor Progression (Garvan Institute of Medical Research)

Postdoctoral Researcher – Genitourinary Cancers (Columbia University)

Senior Endowed Professorship – Cellular Principles & Evolution (Stony Brook University)

Endowed Chair Faculty – Prostate Cancer (Cleveland Clinic Lerner College of Medicine of Case Western Reserve University)

Postdoctoral Position – Prostate Biology (University of Washington)

Postdoctoral Scientist – Prostate Organoids (Rutgers Cancer Institute of New Jersey)

Research Lab Specialist – Tumor Microenvironment & Cell Behavior (University of Southern California)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.